The Human Data Era - Exploring Human Data in Cardiovascular Disease

Heterogeneous disorders such as cardiovascular disease have multiple risk factors, causes, and manifestations. Having a holistic view of a patient’s unique biology potentially leads to earlier and better treatment options.

In this episode, we talk to Narimon Honarpour, vice president of Global Development at Amgen, about how human data is helping drug developers and clinicians unpack the complexities of cardiovascular disease to improve patient outcomes.

To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.

 

Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.

This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.

 

By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.